anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cancer-associated cachexia, a multifactorial syndrome involving loss of muscle mass and anorexia, affects the survival of cancer patients. Anamorelin was the first drug approved in Japan for the treatment of cachexia. However, cases in which anamorelin is discontinued within 3 weeks are often observed in clinical practice. This study aimed to explore the factors associated with continued anamorelin dosing. We retrospectively reviewed records of patients with lung, gastric, pancreatic, and colorectal cancer who started anamorelin at Fukuoka University Hospital from April 2021 to November 2022. Patients were divided into two groups based on the duration of anamorelin administration: 15 patients were classified into the <3 weeks group and 22 were classified into the ≥3 weeks group. The primary objective was to explore the potential factors associated with the continuation of anamorelin, and the secondary objectives were to compare survival and nutritional indices. In the univariate analysis, there were significant differences between the two groups in terms of cancer type (p=0.007) and serum albumin level (p=0.026). In the multivariate analysis, gastric cancer and albumin 2.7 g/dL or less were associated with the continuation of anamorelin. Survival was significantly shorter in the <3 weeks group (p=0.019). This study suggests that the continuation of anamorelin may be influenced by specific tumor types and serum albumin levels. Furthermore, the duration of anamorelin administration may affect patient survival.
Consists of 10 cognitively normal, non-DS individuals, age-matched to the DS adult group. Interventions include biospecimen collection, cognitive assessments, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
Participants receive concurrent chemoradiotherapy. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m\^2 IV or carboplatin (AUC=2) once per week (QW) for 5 or 6 weeks plus external beam radiotherapy followed by brachytherapy not to exceed 8 weeks.
In mammals, brown adipose tissue (BAT) and inguinal white adipose tissue (iWAT) execute sequential thermogenesis to maintain body temperature during cold stimuli. BAT rapidly generates heat through brown adipocyte activation, and further iWAT gradually stimulates beige fat cell differentiation upon prolonged cold challenges. However, fat depot-specific regulatory mechanisms for thermogenic activation of two fat depots are poorly understood. Here, we demonstrate that E3 ubiquitin ligase RNF20 orchestrates adipose thermogenesis with BAT- and iWAT-specific substrates. Upon cold stimuli, BAT RNF20 is rapidly downregulated, resulting in GABPα protein elevation by controlling protein stability, which stimulates thermogenic gene expression. Accordingly, BAT-specific Rnf20 suppression potentiates BAT thermogenic activity via GABPα upregulation. Moreover, upon prolonged cold stimuli, iWAT RNF20 is gradually upregulated to promote de novo beige adipogenesis. Mechanistically, iWAT RNF20 mediates NCoR1 protein degradation, rather than GABPα, to activate PPARγ. Together, current findings propose fat depot-specific regulatory mechanisms for temporal activation of adipose thermogenesis.
Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
Participants received a matching placebo to AG-348 tablets, for a period of 12 weeks as an optimized dose. This was followed by matching placebo further, for a period of 12 weeks as a fixed-dose.
Serious games are innovative computer-based interventions to support children and adults with Autism Spectrum Disorder (ASD). However, few studies have assessed the efficacy of these interventions in real-life contexts. The present study investigates the generalisation of daily living skills related to shopping activities after a rehabilitation intervention administered via a personalised serious game (ShopAut). The underlying hypothesis of this study is that training with an individualised serious game can improve performance in a real-life environment. In order to prove this hypothesis, a small sample of subjects with ASD will play an individualised serious game, ShopAut, for ten sessions. Subjects will undergo real-life experiences in a supermarket pre- and post-virtual training to determine whether there had been a generalisation of skills from the virtual environment to the real environment. Improvements in skills and performance in the real shopping activity are evaluated using specific tools.

The serious game ShopAut is developed integrating an individualised design that provides both the personalisation of the game's scenario, contents, difficulty, and user interface; and the customisation of game modes, player perspectives, and input devices. It is a three-dimensional game that provides a realistic shopping experience where the player can practice and engage with, above all, shopping activities, experiment their problem-solving skills, and take on unexpected events.
A compound of formula <FORM:1034189/C4-C5/1> is obtained by dehydrating a compound of formula <FORM:1034189/C4-C5/2> by adding it drop by drop to heated aluminium phosphate, magnesium oxide, alumina, iron oxide, glass or pumice, at reduced pressure.ALSO:Vitamin A acid esters are obtained by dehydrating a compound of formula <FORM:1034189/C2/1> to give a compound of formula <FORM:1034189/C2/2> reacting compound II with a Grignard reagent or organolithium compound to obtain an organometallic compound and then with a gammaoxosenecioate to give a compound of formula <FORM:1034189/C2/3> partially hydrogenating Compound III to give a compound of formula <FORM:1034189/C2/4> and dehydrating Compound IV to give the Vitamin A acid ester of formula <FORM:1034189/C2/5> where R is a hydrocarbon residue.  Compound I may be dehydrated by adding it drop by drop to heated aluminium phosphate at reduced pressure; magnesium oxide, alumina, iron oxide, glass or pumice may be used instead of aluminium phosphate.  Compound IV is obtained by catalytic hydrogenation of compound III, e.g. with Raney nickel, and compound IV may be dehydrated by reaction with pyridine and phosphorus oxychloride in benzene. Compounds II, III and IV are novel. Examples are given.
Group 3 : "Ketoprofen half-dose" (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours.
FIELD: medicine, particularly, medicinal preparations used for correcting immune response. SUBSTANCE: this oligofurostanoside-based drug is prepared from suspension culture of deltoid diascorea and employed as immunomodulator. Selective effect is produced by disclosed preparation on structure and function of membranes of immunocompetent cells. Novel drug is classed among water-soluble antioxidants of biogenic type. EFFECT: no nephrotoxic effect. 4 tbl
Viruses can cause many human diseases. Three types of human diseases caused by viruses are discussed in this chapter: infectious diseases, autoimmune diseases, and cancers. The infectious diseases included in this chapter include three respiratory tract diseases: influenza, COVID-19, and respiratory syncytial virus. In addition, the mosquito-borne dengue virus diseases are discussed. Vitamin D can reduce risk, severity, and mortality of the respiratory tract diseases and possibly for dengue virus. Many autoimmune diseases are initiated by the body's reaction to a viral infection. The protective role of vitamin D in Epstein-Barr virus-related diseases such as multiple sclerosis is discussed. There are a few cancers linked to viral infections. Such cancers include cervical cancer, head and neck cancers, Hodgkin's and non-Hodgkin's lymphoma, and liver cancer. Vitamin D plays an important role in reducing risk of cancer incidence and mortality, although not as strongly for viral-linked cancers as for other types of cancer.
This is a randomized (study drug assigned by chance), open-label (all people involved know the identity of the intervention), single dose, crossover (volunteers will receive different interventions sequentially during the trial) study in healthy volunteers. The trial will evaluate the levels of TMC435 in the blood circulation after a single dose of 150 mg TMC435 as a capsule formulation taken fasted (Treatment A) and following a meal (Treatment B). In addition, the study will evaluate the levels of TMC435 in the blood circulation after intake of a single dose of 150 mg TMC435 as 2 different tablet formulations (Treatments C and D). There will be a 14-day washout period between treatments and a 4-5 week follow-up at the end. Each volunteer will receive all four treatments. The main focus of the trial is the pharmacokinetic characteristics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of the different formulations. This evaluation requires multiple blood samples from Day 1 through 72 hours after dosing. Safety assessments (lab work, blood pressure, pulse and electrocardiogram) will follow a different schedule and are measured on Day -1 (day prior to taking first dose of drug), Day 1 (day of first dosing) and/or Day 4 of each treatment period, and 4 weeks after the last treatment. Each volunteer will receive 4 treatments, about 14 days apart from each other. Each treatment consists of one single dose of 150 mg TMC435.
BACKGROUND: Targeting ACC1 (acetyl coenzyme A carboxylase 1) to restore the balance between T-helper 17 (Th17) cells and regulatory T cells (Tregs) through metabolic reprogramming has emerged as a promising strategy for reducing neuroinflammation following stroke. We examined the roles of potential miRNAs in regulating ACC1 expression in Tregs and treating ischemic stroke.
METHODS: The expression of miR-24-3p in CD4+T cells of mice was confirmed. Then the protective effects of Ago-24-3p in a mouse model of prolonged occlusion of the distal middle cerebral artery (dMCAO) were examined. We analyzed the infiltration of Tregs and CD3+T cells into the brain and evaluated the improvement of neurological deficits induced by Ago-24-3p using the Modified Garcia Score and foot fault testing.
RESULTS: Our investigation revealed that miR-24-3p specifically targets ACC1. Elevated levels of miR-24-3p have been demonstrated to increase the population of Tregs and enhance their proliferation and suppressive capabilities. Conversely, targeted reduction of ACC1 in CD4+T cells has been shown to counteract the improved functionality of Tregs induced by miR-24-3p. In a murine model of dMCAO, administration of Ago-24-3p resulted in a substantial reduction in the size of the infarct within the ischemic brain area. This effect was accompanied by an upregulation of Tregs and a downregulation of CD3+T cells in the ischemic brain region. In ACC1 conditional knockout mice, the ability of Ago-24-3p to enhance infiltrating Treg cells and diminish CD3+T cells in the ischemic brain area has been negated. Furthermore, its capacity to reduce infarct volume has been reversed. Furthermore, we demonstrated that Ago-24-3p sustained improvement in post-stroke neurological deficits for up to 4 weeks after the MCAO procedure.
CONCLUSIONS: MiR-24-3p shows promise in the potential to reduce ACC1 expression, enhance the immunosuppressive activity of Tregs, and alleviate injuries caused by ischemic stroke. These discoveries imply that miR-24-3p could be a valuable therapeutic option for treating ischemic stroke.
Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting diuretics, increasing the potential for Torsade de Pointes. Potassium levels should be within the normal range prior to administration of dofetilide and maintained in the normal range during administration of dofetilide (see DOSAGE AND ADMINISTRATION). 

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents

The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. Such drugs include phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones. Class I or Class III antiarrhythmic agents should be withheld for at least three half-lives prior to dosing with dofetilide. In clinical trials, dofetilide was administered to patients previously treated with oral amiodarone only if serum amiodarone levels were below 0.3 mg/L or amiodarone had been withdrawn for at least three months.
Group smoking cessation programme. One 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) comprising of Allen Carr's Easyway method being delivered in a spoken form.
The present invention concerns therapeutic agents that modulate the activity of CT receptor. In accordance with the present invention, modulators of CT receptor comprise: a. a CT receptor modulating domain, preferably the amino acid sequence of SEQ ID NO:7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the CT receptor modulating domain. The vehicle and the CT receptor modulating domain may be linked through the N- or C-terminus of the CT receptor modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred CT receptor modulating domains comprise the amino acid sequences described in Table 1. Other CT receptor modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Further in accordance with the present invention is a process for making CT receptor modulators, which comprises: a. selecting at least one peptide that binds to the CT receptor; and b. covalently linking said peptide to a vehicle. The preferred vehicle is an Fc domain. Step (a) is preferably carried out by selection from the peptide sequences in Table 1 hereinafter or from phage display, RNA-peptide screening, or the other techniques mentioned herein.
A system and method for optimizing low density lipoprotein cholesterol (LDL-C) concentration detection is disclosed. The 16 primary influence indexes obtained by the daily direct detection method are utilized, the correlation among the indexes is calculated through multiple linear regression, and the index which has strong correlation with the concentration of low density lipoprotein cholesterol (LDL-C) is screened out and used as the secondary influence index. And establishing an LDL-C prediction model under the secondary influence index by using the BP neural network. At the same time, nuclear magnetic resonance spectroscopy (NMR) detection is used to derive concentration and type information about the different lipid particles. And (3) importing the obtained related secondary influence index detection concentration data into a prediction model for prediction, summarizing the obtained result and the actual measurement result, and carrying out weighted average by using an entropy weight method to obtain an accurate result report of the concentration of LDL-C. The invention reduces the specificity problem of the current LDL-C determination method, reduces the difference caused by the standardization of different test methods, and provides more accurate results for clinical diagnosis.
The present invention relates to the improvement of food items through the increased utilization of plant-derived stearidonic acid in a composition that also lowers linolenic acid content. Many long chain fatty acids have been classified as being Omega 3 and have been shown to provide several health benefits, including heart health. According to the current invention plant-derived stearidonic acid (18:4.omega.3) has been incorporated into a wide range of food products by using a low linolenic acid base composition to enhance stability and shelf life while reducing the need for hydrogenation. The product composition can be used either as an oil oil-based composition or a flour processed from soybeans with enhanced levels of stearidonic acid. These foods range from oil-based products (salad dressing, mayonnaise) to dairy products (milk, cheese) to prepared foods (entrees, side dishes). In addition to improved health benefits the current invention provides food rich in Omega-3 fatty acids that have enhanced storage and/or shelf life characteristics.
Participants in this arm will take a vicodin tablet every 4-6 hrs as needed to a maximum of 8 tablets after surgery. Each tablet has 300 mg acetaminophen and 5 mg hydrocodone. Pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
The invention provides a protein waterA de-targeting chimera and uses thereof. The technical scheme develops a novel PROTAC degrader compound 21a based on BMS-37 small molecules. This is an example of a membrane protein degradation based on a ligand that binds to the extracellular domain of the PD-L1 protein. Can effectively degrade PD-L1 in various malignant tumor cells. As can be seen from the results of in vivo studies, after the compound 21a is treated, the level of PD-L1 in tumors can be remarkably reduced, and CD8 is promoted  +  Infiltration of T cells and significant inhibition of growth of MC-38 cells of colorectal cancer in mice. The ProTAC molecule holds promise as one of the novel and alternative strategies for cancer immunotherapy.
Prodn. of human prolactin(I) comprises (a) transplanting human cells capable of producing (I) into any warm-blooded animal other than a human, or by propagating the cells in a device, esp., a diffusion chamber which supplies them with nutrient body fluid directly from warm-blooded animals.  (b) the grown cells are then treated with inducer.  The (I)-inducer includes reserpine, phenothiazine, chlorpromazine, a hormone such as estrogen, amino acids such as Lys, Arg, or Cys, salts such as NaCl, KCl, or MgSO4 and a mixt. of salts. Suitable human cells include anterior hypophysis acidophilic cells, viral transformed or X-irradiated cells, hypophysis acidophilic adenoma cells, pulmonary carcinoma cells, and cell lines established from these cells. (I) stimulates development of the mammary gland, prostate, and seminal vesicles.
A powder composition containing e.g. amantadine aminosulfate as the active ingredient contains a gas forming agent (sodium bicarbonate) and a salt of an edible organic acid, which on mixing with water reacts very slowly with the bicarbonate, allowing the active ingredient to suspend itself in the water rather than accumulating in a foamy layer on the surface. A powder composition for dissolving in water contains acidic and gas-generating components and one or more pharmaceuticals, along with other additives such as flavourings, sweeteners or fillers. The novelty is that the active ingredient(s) are in the form of small granules (the active phase) mixed with one or more salts of an edible organic acid; the granules also comprise one or more binders and/or some of the gas-forming agent. The active phase is then mixed with a powder base comprising the other additives and optionally formed into tablets. An Independent claim is also included for preparation of the composition.
PURPOSE:To obtain a cosmetic having high safety, excellent feeling and physical properties and low oiliness, and giving refreshing, moist and smooth feeling to the skin, by compounding an oil derived from a deep-sea fish. CONSTITUTION:The objective cosmetic is prepared by using a clear liquid wax having light yellow color, obtained from a deep-sea fish, and composed mainly of an ester of an unsaturated fatty acid and an unsaturated alcohol, as an active component. The deep-sea fish is e.g. orange raffy, Ruvettus pretiosus, coelacanth, ABURASOKOMUTSU, KUROMATOODAI, etc. For example, the oil is collected from the tissue between the skin and the flesh of orange raffy which is a representative deep-sea fish which can be fished in a particular area near New Zealand at a depth of 1,000m. The constituent components of the oil are composed of 16-20C unsaturated fatty acids and 18-22C unsaturated alcohols. The stability of the cosmetic is improved by using the oil in combination with an antioxidant such as vitamin E, BHT, BHA, anthracine, etc.
The invention discloses a traditional Chinese medicinal preparation for treating children's virus myocarditis. The traditional Chinese medicinal preparation is prepared from the following raw materials: 25-35 grams of astragalus membranaceus, 25-35 grams of radix ophiopogonis, 25-35 grams of cortex phellodendri, 15-25 grams of trogopterus dung, 15-25 grams of semen ziziphi spinosae, 15-25 grams of rhizoma atractylodis, 15-25 grams of rhizoma curculiginis, 5-15 grams of radix cynanchi panicullati, 5-15 grams of fried atractylodes macrocephala and 5-15 grams of thorn apples. A preparation method comprises the steps of mixing the medicinal raw materials, decocting the medicinal raw materials with water for 1-2 hours, filtering to obtain a filtrate, then decocting filter residues with water for 0.5-1.5 hours, filtering to obtain a filtrate, combining the two filtrates, and concentrating the combined filtrates until the relative density is 1.22-1.24 (50 DEG C) to obtain the traditional Chinese medicinal preparation. During treatment, a patient orally takes the traditional Chinese medicinal preparation twice every day. Generally, the virus myocarditis can be cured after the patient takes the traditional Chinese medicinal preparation for about a month. The traditional Chinese medicinal preparation for treating the virus myocarditis of children has an outstanding treating effect and a quick response and does not have toxic and side effects, and the total efficiency is 97.1 percent.
This is a single arm trial. Participants will receive SHR1210 + GEMOX treatment.
Part B: Participants with infantile- or later-onset SMA will receive loading doses of 12 mg of nusinersen intrathecally on Days 1, 15, 29, and 64 followed by maintenance doses of 12 mg on Days 183 and 279. Sham procedure will be administered on Day 135.
Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
The OB2-1 transcription activator, antibodies reactive thereto and genes encoding OB2-1 are described. Compounds interfering with the binding of OB2-1 to its binding site. Measurement of the abundance OB2-1 in tumours may be used as a prognostic marker and to indicate which tumours are suitable for treatment with the DNA construct and compounds of the invention. A DNA construct comprising (i) a promoter segment which specifically binds the c-erbB-2-binding nuclear transcription activator and, under transcriptional regulation thereby, (ii) a heterologous coding sequence. The construct is introduced into tumour cells, where the promoter provides for tumour-specific expression of the heterologous coding sequence, which encodes a directly or indirectly toxic substance, such as cytosine deaminase (CD). CD converts the pro-drug 5-fluorocytosine into the more toxic 5-fluorouracil.